Iterum Therapeutics plc (ITRM)
$0.03+0.00%Close
SELLCRISIS · day 41
Key stats
- Market cap
- $2M
- Beta
- 3.01
- P/E (TTM)
- -0.08
- 1W
- -82.35%
- 1M
- -80.00%
- vs SPY 1W
- -81.37%
- vs SPY 1M
- -81.86%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 7
- GROWTH
- 20
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC164.9%
REV YoY-
ROE274.9%
EPS YoY-
ROA-47.7%
GROSS-84
OP-3311
NET-3971
[VALUATION]
P/E TTM-0.08
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-0.19
P/FCF-
EV/EBITDA-1.78
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO2.13
ND/EBITDA-
BETA3.01
Company news
FAQ
- What is LOPJLB’s current signal on ITRM?
- LOPJLB’s latest quantitative signal on Iterum Therapeutics plc (ITRM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ITRM in?
- Iterum Therapeutics plc (ITRM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Iterum Therapeutics plc (ITRM) do?
- Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced…